31 Meineche-Schmidt V, Krag E. Antisecretory therapy in 1017 patients with ulcer-like or reflux-like dyspepsia in general practice. Eur J Gen Pract 1997 ; 3 : 125-30.

32Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia : Randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000 ; 92 : 1881-8.

33Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection : A prospective, randomized study. Gastroenterology 2000 ; 119 : 7-14.

34Leung WK, Lin SR, Ching JY, To KF, et al. Factors predicting progression of gastric intestinal metaplasia : Results of a randomised trial on Helicobacter pylori eradication. Gut 2004 ; 53 : 1244-9.

35Wong BC, Lam SK, Wong WM, et al. China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China : A randomized controlled trial. JAMA 2004 ; 291 : 187-94.

36Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori : A combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001 ; 49 : 347-53.

37Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori and the development of gastric cancer. N Engl J Med 2001 ; 345 : 784-9.

38Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997 ; 6 : 639-42.

39 Duggan A, Elliott C, Logan RPH, et al. Does near patient H. pylori testing in primary care reduce referral for endoscopy ? Results from a randomized trial (abstr). Gastroenterology 1998 ; 114 : 2615.

40Allison JE, Hurley LB, Hiatt RA, et al. A randomized controlled trial of test-and-treat strategy for Helicobacter pylori : Clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease. Arch Intern Med 2003 ; 163 : 1165-71.

41Manes G, Menchise A, de Nucci C, et al. Empirical prescribing for dyspepsia : Randomised controlled trial of test and treat versus omeprazole treatment. BMJ 2003 ; 326 : 1118-24.

42Delaney BC, Wilson S, Roalfe A, et al. Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years : A randomised controlled trial in primary care. Lancet 2000 ; 356 : 1965-9.

43Chiba N, Van Zanten SJ, Sinclair P, et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia : The Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002 ; 324 : 1012-6.

44Ladabaum U, Fendrick AM, Glidden D, et al. Helicobacter pylori test-and-treat intervention compared to usual care in primary care patients with suspected peptic ulcer disease in the United States. Am J Gastroenterol 2002 ; 97 : 3007-14.

45 Jarbol D, Kragstrup J, Havelund T, et al. Efficacy of three strategies based on empirical antisecretory therapy and Helicobacter pylori status for management of dyspepsia in general practice (abstr). Gastroenterology 2004 ; 126 : A69.

46Moayyedi P, Axon AT. The usefulness of the likehood ratio in the diagnosis of dyspepsia and gastrœsophageal reflux disease. Am J Gastroenterol 1999 ; 94 : 3122-5.

47Moayyedi P, Delaney B, Vakil N, et al. The efficacy of proton pump inhibitoir in non-ulcer dyspepsia : A systematic review and economic analysis. Gastroenterology 2004 ; 127 : 1329-37.

48Wolfe M, Sachs G. Acid Supression : Optimizing therapy for gastroduodenal ulcer healing, gastrœsophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000 ; 118 : S9-S31.

49Bramble MG, Suvakovic Z, Hungin AP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy, Gut 2000 ; 46 : 464-7.

50Lassen A, Hallas J, de Muckadell OB, et al. The risk of missed gastro esophageal cancer diagnoses in users and non users of antisecretory medication. Gastroenterology 2005 ; 129 : 1179-86.

51Scolapio JS, Camilleri M. Nonulcer dyspepsia. Gastroenterologist 1996 ; 4 : 13-23.

52Quartero A, de Wit NJ, Lodder AC, et al. Disturbed solid-phase gastric emptying in functional dyspepsia : A meta-analysis. Dig Dis Sci 1998 ; 43 : 2028-33.

53Agreus L, Svardsudd K, Nyren O, et al. Irritable bowel syndrome and dyspepsia in the general population : Overlap and lack of stability over time. Gastroenterology 1995 ; 109 : 671-80.

54Thompson WG, Longstreth G, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999 ; 45(Suppl 2) : 43-7.

55Vesa TH, Seppo LM, Marteau PR, et al. Role of irritable bowel syndrome in subjective lactose intolerance. Am J Clin Nutr 1998 ; 67 : 710-5.

56Ladabaum U, Fendrick AM, Scheiman JM. Outcomes of initial noninvasive Helicobacter pylori testing in US primary care patients with uninvestigated dyspepsia. Am J Gastroenterol 2001 ; 96 : 2051-7.

57Fendrick AM, Chernew ME, Hirth RA, et al. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med 1995 ; 123 : 260-8.

58Silverstein MD, Petterson Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia : A decision analysis. Gastroenterology 1996 ; 110 : 72-83.

59Ofman JJ, Etchason J, Fullerton S, et al. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia : Clinical and economic consequences Ann Intern Med 1997 ; 126 : 280-91.

60Briggs AH, Sculpher M, Logan RP, et al. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. BMJ 1996 ; 312 : 1321-5.

61 Ofman JJ, Rabeneck L . The effectiveness of endoscopy in the management of dyspepsia : A qualitative systematic review. Am J Med 1999 ; 106 : 335-46.

62Rabeneck L. Managing dyspepsia : Is prompt endoscopy the way to go ? Gastroenterology 1995 ; 108 : 1324.

63Vaira D, Menegatti M, Miglioli M. What is the role of Helicobacter pylori in complicated ulcer disease ? Gastroenterology 1997 ; 113 : S78-S84.

65Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2002 Consensus Report. Aliment Pharmacol Ther 2002 ; 16 : 167-80.

66Ford AC, Qume M, Moayyedi P, et al. Helicobacter pylori « Test and Treat » or Endoscopy for Managing Dyspepsia : An Individual Patient Data Meta-analysis. Gastroenterology 2005 ; 128 : 1838-44.

67Lassen P, Bytzer P, Schaffalitzky, et al. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients : A randomised trial. Lancet 2000 ; 5 : 455-60.

68Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ 2000 ; 16 ; 321 : 659-64.

69Heaney A, Collins JS,Watson RG, et al. A prospective randomised trial of a « test and treat » policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999 ; 45 : 186-90.

70Delaney BC, Wilson S, Roalfe A, et al. Randomised controlled trial of Helicobacter pylori testing and endoscopy for dyspepsia in primary care. BMJ 2001 ; 322 : 898-901.

71Chiba N, Van Zanten SJ, Sinclair P, et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia : The Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002 ; 324 : 1012-6.

72Delaney BC, Innes MA Deeks J, et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2001 ; (3) : CD001961.

73 Thijs JC, van Zwet AA. Approach to treatment of dyspepsia in primary care : A randomized trial comparing « test-and-treat » with prompt endoscopy. Arents NL. Arch Intern Med 2003 ; 163 : 1606-12.

74Manes G, Menchise A, de Nucci C, et al. Empirical prescribing for dyspepsia : Randomised controlled trial of test and treat versus omeprazole treatment. BMJ 2003 ; 326 : 1118.

75Allison JE, Hurley LB, Hiatt RA, et al. A randomized controlled trial of test-and-treat strategy for Helicobacter pylori : Clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease. Arch Intern Med 2003 ; 163 : 1165-71.

76Bytzer P, Hansen,JM, de Muckadell S. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994 ; 343 : 811-6.

77Veldhuzen van Zanten S, Flook N, Chiba N, et al. An evidence-based approch to the management of uninvestiguated dyspepsia in the era of Helicobacter pylori. CMAJ 2000 ; 162(12 Suppl) : S3-S23.

78Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence : A review. Gastroenterology 1996 ; 110 : 1244-52.

79Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care : A decision analysis of competing strategies. Gastroenterology 2002 ; 122 : 1270-85.

80 Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated ? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998 ; 9 : 1409-15.

81 Ford AC, Delaney B, Forman D, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive Patients. Cochrane Database Syst Rev 2006 ; (2) : CD003840.

82Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988 ; 2 : 1437-42.

83Forbes GM, Glaser ME, Cullen DJ, et al. Duodenal ulcer treated with Helicobacter pylori eradication : Seven years follow-up. Lancet 1994 ; 343 : 258-60.

84 Van der Hulst RWM, Rauws EAJ, Köycü B, et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori : A prospective long-term follow up study. Gastroenterol 1997 ; 113 ; 1082-6.

85Wihelmsen I, Berstad A. Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter pylori. Scand J Gastroenterol 1994 ; 29 : 874-9.

86Axon ATR, O’Morain CA, Bardhan KD, et al. Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection. BMJ 1997 ; 314 : 565-75.

87Lucock MP, Morley S, White C, et al. Responses of consecutive patients to reassurance after gastroscopy : Results of self administered questionnaire survey. BMJ 1997 ; 315 : 572-5.

88Wiklund I, Glise H, Jerndal P, et al. Does endoscopy have a positive impact on quality of life in dyspepsia ? Gastrointest Endosc 1998 ; 47 : 449-54.

89Quadri A, Vakil N. Health-related anxiety and the effect of open-access endoscopy in US patients with dyspepsia. Aliment Pharmacol Ther 2003 ; 17 : 835-40.

90Hungin A, Thomas P, Bramble M, et al. What happens to patients following open access gastroscopy ? An outcome study from general practice. Br J Gen Pract 1994 ; 44 : 519-21.

91Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998 ; 93 : 2330-8.

92Graham DY, Opekun AR, Hammoud F, et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 2003 ; 98 : 1005-9.

93Vaira D, Malfertheiner P, Megraud F, et al. HPSA. European Study Group. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. Lancet 1999 ; 354 : 30-3.

94Vaira D, Vakil N, Menegatti M, et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002 ; 136 : 280-7.

95Braden B, Teuber G, Dietrich CF, et al. Comparison of new faecal antigen test with (13)C-urea breath test for detecting Helicobacter pylori infection and monitoring eradication treatment : Prospective clinical evaluation. BMJ 2000 ; 320 : 148.

96Trevisani L, Sartori S, Galvani F, et al. Evaluation of a new enzyme immunoassay for detecting Helicobacter pylori in feces : A prospective pilot study. Am J Gastroenterol 1999 ; 94 : 1830-3.

97Vaira D, Vakil N, Menegatti M, et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002 ; 136 : 280-7.

98Loy CT, Irwing LM, Katelaris PH, et al. Do commercial serological kits for Helicobacter Pylori infection differ in accuracy ? A meta-analysis. Am J Gastroenterol 1996 ; 91 : 1138-44.

99Feldman M, Cryer B, Lee E, Peterson WL. Role of seroconversion in confirming cure of Helicobacter pylori infection. JAMA 1998 ; 280 : 363-5.

100Gisbert JP, Gonzales L, Calvet X, et al. Proton pump inhibitors, clarythromycin and either amoxycyllin or nitroimidazole : A meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000 ; 14 : 1319-28.

101Collins J, Ali-Ibrahim A, Smoot DT, et al. Antibiotic therapy for Helicobacter pylori. Med Clin N Am 2006 ; 90 : 1225-40.

102Graham DY. Therapy of Helicobacter pylori : Current status and Issues. Gastroenterology 2000 ; 118 : S2-S8.

103Gisbert JP, Pajares JM. Review article : Helicobacter pylori « rescue » regimen when proton pump inhibitor – based therapies fail. Aliment Pharmacol Ther 2002 ; 16 : 1047-57.

104Gisbert JP, Pajares JM. Helicobacter pylori « rescue » therapy after failure of two eradication treatments. Helicobacter 2005 ; 10 : 363-72.

105Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence : A review. Gastroenterology 1996 ; 110 : 1244-52.

106Ford AC, Delaney B, Forman D, et al. Eradication therapy in Helicobacter pylori positive peptic ulcer disease : Systemic review and economic analysis. Am J Gastroenterol 2002 ; 99 : 1833-55.

107Ong SP, Duggan A. Eradication of Helicobacter pylori in clinical situations. Clin Exp med 2004 ; 4 : 30-8.

Bytzer P, O’Morain C. Treatment of Helicobacter pylori. Helicobacter 2005 : 10(Suppl 1) : 40-6.

108McLoughlin RM, O’Morain CA, O’Connor HJ. Eradication of Helicobacter pylori : Recent advances in treatment. Fund Clin Pharmacol 2005 ;19 : 421-7.

109Candelli M, Nista EC, Carloni E, et al. Treatment of H. pylori infection : A review. Curr Med Chem 2005 ; 12 : 375-84.

110Megraud F, Marshall BJ. How to treat Helicobacter Pylori : First-Line, Second-Line, and future Therapies. Gastroenterol Clin of North Am 2000 ; 29 : 759-72.

111Barki J, Blanc P, Michel J, et al. Le syndrome douloureux du rebord costal (ou syndrome de Cyriax). La presse médicale 1996 ; 25 : 973-6.

112Volpi A, Gross, G, Hercogova J et al. Current management of herpes zoster : the European view. Am J Clin Dermatol. 2005 ; 6 : 317-25.

113Qeinberg JM, Scheinfield NS. Cutaneous infections in the elderly : Diagnosis and management. Dermatol Ther. 2003 ; 16 : 195-205.

114Banikarim C. Chacko MR. Pelvic inflammatory disease in adolescents. Adolesc Med Clin 2004 ; 15 : 273-85.

115 Peter NG, Clark LR, Jaeger JR. Fitz-Hugh-Curtis syndrome : A diagnosis to consider in women with right upper quadrant pain. Cleve Clin J Med 2004 ; 71 : 233-9.

116Zeger W, Holt K. Gynecologic infections. Emerg Med Clin North Am 2003 ; 21 : 631-48.

117Mc Garrity TJ, Peters DJ, Thompson C, et al. Outcome of patients with chronic abdominal pain referred to chronic pain clinic. Am J Gastroenterol 2000 ; 95 : 1812-6.

118Srinivasan R, Greenbaum DS. Chronic abdominal wall pain : A frequently overlooked problem. Practical approach to diagnosis and management. Am J Gastroenterol 2002 ; 97 : 824-30.

119 Locke GR , Murray JA, Zinsmeister AR, et al. Celiac disease serology in irritable bowel syndrome and dyspepsia : A population-based case-control study. Mayo Clin Proc 2004 ; 79 : 476-82.

120Lucock MP, Morley S, White C, et al. Response of consecutive patients to reassurance after gastroscopy : Results of self administrered questionnary survey. BMJ 1997 ; 315 : 572-5.

121Quadri A,Vakil N. Health-related anxiety and the effect of open-access endoscopy in US patients with dyspepsia. Aliment Pharmacol Ther 2003 ; 17 : 835-40.

122Wiklund I, Glise H, Jerndal P, et al. Does endoscopy have a positive impact on quality of life in dyspepsia ? Gastrointest Endosc 1998 ; 47 : 449-54.

123Rabeneck L, Wristers K, Souchek J, et al. Impact of upper endoscopy on satisfaction in patients with previously uninvestigated dyspepsia. Gastrointest Endosc 2003 ; 57 : 295-9.

124Hungin A, Thomas P, Bramble M, al. What happens to patients following open access gastroscopy ? An outcome study from general practice. Br J Gen Pract 1994 ; 44 : 519-21.

125Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori : A combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001 ; 49 : 347-53.

126Saacson PG. Update on MALT lymphomes. Best Pract Res Clin Haematol 2005 ; 18 : 57-68.

127Jyotheeswaran S, Shah AN, Jin HO, et al. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY : Is empirical triple therapy justified ? Am J Gastroenterol 1998 ; 93 : 574-8.

128Ciociola AA, McSorley DJ, Turner K, et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999 ; 94 : 1834-40.

129Reinbach DH, Cruickshank G, McColl KE. Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection. Gut 1993 ; 34 : 1344-7.

130Laine LA. Helicobacter pylori and complicated ulcer disease.Am J Med 1996 ; 100 : 52S-57S.

131Hopper N, Stephens MR, Blackschaw G, et al. Relative value of repeat gastric ulcer surveillance gastroscopy in diagnosing gastric cancer. Gastric Cancer 2006 ; 9 : 217-22.

132Orlowska J, Jarosz D, Pachlewski J, et al. Malignant transformation of benign epithelial gastric polyps. Am J Gastroenterol 1995 ; 90 : 2152-9.

133Kraag N, Thijs C, Knipschild P. Dyspepsia-how noisy are gallstones ? A meta-analysis of epidemiologic studies of biliary pain, dyspeptic symptoms, and food intolerance. Scand J Gastroenterol 1995 ; 30 : 411-21.

134Berger MY, van der Velden JJ, Lijmer JG, et al. Abdominal symptoms : Do they predict gallstones ? Scand J Gastroenterol 2000 ; 35 : 70-7.

135Weinert CR, Arnett D, Jacobs D Jr et al. Relationship between persistence of abdominal symptoms and successful outcome after cholecystectomy. Arch Intern Med 2000 ; 160 : 989-95.

136Sahai AV, Mishra G, Penman ID, et al. EUS to detect evidence of pancreatic disease in patients with persistent or nonspecific dyspepsia. Gastrointest Endosc 2000 ; 52 : 153-9.

137Talley, NJ. Review article : Functional dyspepsia-should treatment be targeted on disturbed physiology ? Aliment Pharmacol Ther 1995 ; 9 : 107-111.

138Williams S, Gillespie P, Little JM. Celiac axis compression syndrome : Factors predicting a favorable outcome. Surgery 1985 ; 98 : 879-87.

139Horton KM, Talamini MA, Fishman EK. Median arcuate ligament syndrome : Evaluation with CT angiography. Radiographics 2005 ; 25 : 1177-82.

140Drossman DA. The functional gastrontestinal disorders and the Rome III process. Gastroenteroloy 2006 ; 130 : 1377-90.

141Jones R, Lydeard S. Dyspepsia in the community : A follow-up study. Br J Clin Pract 1992 ; 46 : 95-7.

142Tack J. Piessevaux H, Coulie B, et al. Role of impaired gastric accommodation to a meal in functional dyspepsia Gastroenterology 1998 ; 115 : 1346-52.

143Salet GA, Samsom M, Roelofs JM, et al. Responses to gastric distension in functional dyspepsia. Gut 1998 ; 42 : 823-9.

144Mertz H, Fullerton S, Naliboff B, et al. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut 1998 ; 42 : 814-22.

145Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003 ; 1 : CD002096.

146Scolapio JS, Camilleri M. Nonulcer dyspepsia. Gastroenterologist 1996 ; 4 : 13-23.

147Haug TT, Svebak S, Wilhelmsen I, et al. Psychological factors and somatic symptoms in functional dyspepsia. A comparison with duodenal ulcer and healthy controls. J Psychosom Res 1994 ; 38 : 281-91.

148Saad RJ,Chey D. Review article : Current and emerging therapies for functional dyspepsia. Aliment Pharmacol Ther 2006 ; 24 : 475-92.

149Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003 ; 1 : CD001960.

150Blum AL, Talley NJ, O’Morain C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998 ; 339 : 1875-81.

151McColl K, Murray L, El-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998 ; 339 : 1869-74.

152Talley NJ, Vakil N, Ballard ED, et al. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. Engl J Med 1999 ; 341 : 1106-11.

153MacNamara D, Buckley M, Gilvarry J, et al. Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia : A 5-year follow-up study. Helicobacter 2002 ; 7 : 317-21.

154Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with non-ulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Inter Med 2001 ; 134 : 361-9.

155Moayyedi P, Deeks J, Talley NJ, et al. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia : Resolving the discrepany between systematic reviews. Am J Gastroenterol 2003 ; 98 : 2621-6.

156Blum AL, Arnold R, Stolte M, et al. Short course acid suppressive treatment for patients with functional dyspepsia : Results depend on Helicobacter pylori status. Gut 2000 ; 47 : 473-80.

157 Shiau, JY, Shukla, VK, Dube, C. The efficacy of proton pump inhibitors in adults with functional dyspepsia. Technology Report No. 22 Ottawa : Canadian Coordinating Office for Health Technology Assessment (CCOHT) ; 2002.

158Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia : A systematic review and economic analysis. Gastroenterology 2004 ; 127 : 1329-37.

159Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia : Double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998 ; 12 : 1055-65.

160Peura DA, Kovacs TO, Metz DC, et al. Lansoprazole in the treatment of functional dyspepsia : Two double-blind, randomized, placebo-controlled trials. Am J Med 2004 ; 116 : 740-8.

161Abraham NS, Moayyedi P, Daniels B, et al. Systematic review : The methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Aliment Pharmacol Ther 2004 ; 19 : 631-41.

162Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, et al. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia : A meta-analysis. Am J Gastroenterol 2001 ; 96 : 689-96.

163Soo S, Moayyedi P, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsiaI Cochrane Database Syst Rev 2000 ; (2) : CD001960.

164Jackson JL, O’Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications : A meta-analysis. Am J Med 2000 ; 108 : 65-72.

165Soo S, Forman D, Delaney B, Moayyedi P. A systematic review of psychological therapies for nonulcer dyspepsia. Am J Gastroenterol 2004 ; 99 : 1817-22.

166Hamilton J, Guthrie E, Creed F, et al. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000 ; 119 : 661-9.

167Calvert EL, Houghton LA, Cooper P, et al . Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002 ; 123 : 1778-85.

168 Drossman DA, Creed FH, Olden KW, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gut 1999 ; 45(Suppl 2) : 25-30.

169Drossman DA, Talley JJ, Lesermann J, et al. Sexual and physical abuse and gastrointestinal illness. Review and recommendations. Ann Intern Med 1995 ; 123 : 782-94.

170Talley NJ, Fett SL, Zinsmeister AR, et al. Gastrointestinal tract symptoms and self-reported abuse : A population-based study. Gastroenterology 1994 ; 107 : 1040-9.

171Adang RP, Vismans JF, Talmon JL, et al. Appropriateness of indications for diagnostic upper gastrointestinal endoscopy : Association with relevant endoscopic disease. Gastrointest Endosc 1995 ; 42 : 390-7.

172Sue-Ling HM, Johnston D, Martin IG, et al. Gastric cancer : A curable disease in Britain. BMJ 1993 ; 307 : 591-6.

173Hallissey MT, Allum,WH, Jewkes, AJ, et al. Early detection of gastric cancer. BMJ 1990 ; 301 : 513-5.

174Farinati F, Cardin F, Di Mario F, Vianello F, et al. Early and advanced gastric cancer during follow-up of apparently benign gastric ulcer : Significance of the presence of epithelial dysplasia. J Surg Oncol 1987 ; 36 : 263-7.

175Lundegardh G, Adami HO, Helmick C, et al. Stomach cancer after partial gastrectomy for benign ulcer disease. N Engl J Med 1988 ; 319 : 195-200.

176Stalnikowicz R, Benbassat J. Risk of gastric cancer after gastric surgery for benign disorders. Arch Intern Med 1990 ; 150 : 2022-6.

177Joossens JV, Hill MJ, Elliott P, et al. Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group. Int J Epidemiol 1996 ; 25 : 494-504.

178Tredaniel J, Boffetta P, Buiatti E, et al. Tobacco smoking and gastric cancer : Review and meta-analysis. Int J Cancer 1997 ; 72 : 565-73.

179Barstad B, Sorensen TI, Tjonneland A, et al. Intake of wine, beer and spirits and risk of gastric cancer. Eur J Cancer Prev 2005 ; 14 : 239-43.

180Rugge M, Farinati F, Baffa R, et al. Gastric epithelial dysplasia in the natural history of gastric cancer : A multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology 1994 ; 107 : 1288-96.

181Yamada H, Ikegami M, Shimoda T, et al. Long-term follow-up of gastric adenoma/dysplasia. Endoscopy 2004 ; 36 : 390-6.

182Rugge M, Cassaro M, Di Mario F, et al. The long term outcome of gastric non-invasive neoplasia. Gut 2003 ; 52 : 1111-6.

183Whiting JL, Sigurdsson A, Roelands DC, et al. The long term results of endoscopic surveillance of premaligant gastric lesions. Gut 2002 ; 50 : 378-81.

184Sandler RS, Nyren O, Ekbom A Eisen GM, et al. The risk of esophageal cancer in patients with achalasia. A population-based study. JAMA 1995 ; 274 : 1359-62.

185Streitz JM, Ellis FH, Gibb SP, et al. Achalasia and squamous cell carcinoma of the esophagus : Analysis of 241 patients. Ann Thorac Surg 1995 ; 59 : 1604-9.

186Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline : The role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006 ; 63 : 570-80.

187Brinton LA, Gridley G, Hrubec Z, et al. Cancer risk following pernicious anaemia. Br J Cancer 1989 ; 59 : 810-3.

188Bresky G, Mata A, Llach J, et al. Endoscopic findings in a biennal follow-up program in patients with pernicious anemia. Hepatogastroenterology 2003 ; 50 : 2264-6.

189Ofman JJ, Shaw M, Sadik, et al. Identifying patients with gastrœsophageal reflux disease : Validation of a practical screening tool. Dig Dis Sci 2002 ; 47 : 1863-9.

190The Danish Dyspepsia Group. Value of the unaided clinical diagnosis in dyspeptic patients in primary care. Am J Gastroenterol 2001 ; 96 : 1417-21.

191De Vault RK, Castell DO. Updated Guidelines for the Diagnosis and Treatment of Gastrœsophageal reflux Disease. Am J Gastroenterol 2005 ; 100 : 190-200.

192Capell MS. Clinical presentation, diagnosis and management of gastrœsophageal reflux disease. Med Clin North Am 2005 ; 89 : 243-91.

193El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol 2004 ; 99 : 1877-83.

194Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett’s œsophagus during omeprazole treatment : A randomised double blind study. Gut 1999 ; 45 : 489-94.

195Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastrœsophageal reflux disease : Follow-up of a randomized controlled trial. JAMA 2001 ; 285 : 2331-8.

196Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett’s esophagus : A prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997 ; 92 : 212-5.

197Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett’s esophagus : Observational study. BMJ 2000 ; 321 : 1252-5.

198Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006 ; 4 : 566-72.

199Hameeteman W , Tytgat GN, Houthoff HJ, et al. Barrett’s esophagus : Development of dysplasia and adenocarcinoma. Gastroenterology 1989 ; 96 : 1249-56.

200Skacel M, Petras RE, Gramlich TL,et al. The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am J Gastroenterol 2000 ; 95 : 3383-7.

201Hirota WK, Zuckermann MJ, Adler DG, et al. ASGE guideline : The role of endoscopy for surveillance of premalignant conditions of the upper GI tract. Gastrointest Endocop 2006 ; 63 : 570-80.

202Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol 2002 ; 97 : 1888-9.

203Lundell L, Miettinen P, Myrvold HE, et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastrœsophageal reflux disease. J Am Coll Surg 2001 ; 192 : 172-81.

204Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastrœsophageal reflux disease : Follow-up of a randomized controlled trial. JAMA 2001 ; 285 : 2331-8.

205Iqbal A, Salinas V, Filip CJ. Endoscopic therapies of gastrœsophageal reflux disease. World J Gastroenterol. 2006 ; 12 : 2641-55.

206Falk GW, Fennerty MB, Rothstein RI. AGA institute medical position statement on the use of endoscopic therapy for gastrœsophageal reflux disease. Gastroenterology 2006 ; 131 : 1313-4.

207Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett’s esophagus. Am J Gastroenterol 1998 ; 93 : 711-6.

208Katz PO, Anderson C, Khoury R, et al. Gastro-œsophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998 ; 12 : 1231-4.

209 Graham DY, Opokun AR, Yamaoka H, et al. Early events in proton pump inhibitors-associated corpus gastritis during acid suppressive therapy : Implications for long term safety. Am J Gastroenterol 2003 ; 90 : 1401-6.

210Moayyedi P, Bardhan C, Young L, et al. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastrœsophageal reflux disease in patients with gastrœsophageal reflux disease. Gastroenterology 2001 ; 121 : 1120-6.

211Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-œsophageal reflux disease : A randomised controlled trial. Lancet 2001 ; 357 : 1738-42.

212Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. A Cure of Helicobacter pylori infection in patients with reflux œsophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease : Results of a randomised controlled trial. Gut 2004 ; 53 : 12-20.

213Bergmann JJ. Latest developments in the endoscopic management of gastrœsophageal reflux disease and Barrett’s esophagus : An overview of the year’s literature. Endoscopy 2006 ; 38 : 122-32.

214Schubert MJ, MacGrath, Buenaventura PO. Barrett’s esophagus : Diagnostic approaches and surveillance. Semin Thorac Cardiovasc Surg 2005 ; 17 : 301-12.

215Straus WL, Offman JJ, MacLeanC, et al. Do NSAIDs cause dyspepsia ? A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol 2002 ; 97 : 1951-8.

216Ofman JJ, MacleanCH, starus WL, et al. Meta-analysis of dyspepsia and nonsteroidal anti-inflammatory drugs. Arthritis Rheum 2003 ; 49 : 508-18.

217Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events : Results of a double-blind outcomes in patients with rheumatoid arthritis. Gastroenterology 2002 ; 123 : 1006-12.

218Singh G, Ramey DR,Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern med 1996 : 156 : 1530-6.

219Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991 ; 115 : 787-96.

220Larkai EN, Smith JL, Lidsky MD, et al. Gastroduoedenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal-anti-inflammatory drug use. Am J Gastroenterol 1987 ; 82 : 1153-8.

221Voutilainen M, Mantynen T, Farkkila M, et al. Impact of non-steroidal anti-inflammatory drugs and aspirin on the prevalence of dyspepsia and uncomplicated peptic ulcer disease. Scand J Gastroenterol 2001 ; 36 : 817-21.

222Wilcox CM, Clark WS. Features associated with painless peptic ulcer bleeding. Am J Gastroenterol 1997 ; 92 : 1289-92.

223Shallcross TM, heatley RV. Effect of non-steroidal anti-inflammatory drugs on dyspeptic symptoms. BMJ 1990 ; 300 : 368-9.

224Thiéfin G. Complications digestives des anti-inflammatoires non stéroïdiens. Gastroenterol Clin Biol 2003 ; 27 : 495-523.

225Hawkey C. Nonsteroidal Anti-inflammatory Drug Gastropathy. Gastroenterology 2000 ; 119 : 521-35.

226Cappel MS, Schein JR. Diagnosis and treatment of nonsteroidal anti-inflammatory drug-associated upper gastrointestinal toxicity. Gastroenterol Clin of North Am 2000 ; 29 : 97-124.

227Hunt RH, Bazzoli F. Review article : Should NSAID/low dose aspirine takers be tested routinely for H. pylori infection and treated if positive ? Implications for primary risk of ulcer relapse after initial healing. Aliment Pharmacol Ther 2004 ; 19(Suppl. 1) : 9-16.

228 Lamarque D. Physiopathologie, risque et prévention des lésions ulcérées gastro-duodénales en cas de prise d’anti-inflammatoires non stéroïdiens. Hepato-Gastro 2001 ; 8 : 103-11.

229Chan FKL, Graham DY. Review article : Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications – review and recommendations bases on risk assessment. Aliment Pharmacol Ther 2004 ; 19 : 1051-61.

230Thiéfin G, Bannwarth B. Prise en charge du risque digestif chez les patients traités par AINS. Synthèse et perspectives. Gastroenterol Clin Biol 2004 ; 28 : C96, C102.

231Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999 ; 117: 17-25.

232 Laine L. Review article : Gastrointestinal bleedind with low-dose aspirin-what’s the risk ? Aliment Pharmacol Ther 2006 ; 24 : 897-908.

233Richy F, Bruyere O. Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use : A consensus statement using a meta-analytic approach. Ann Rheum Dis 2004 ; 63 : 759-66.

234Weideman RA, Kelly KC, Kazi S, et al. Risks of clinically significant upper gastrointestinal events with etodolac and naproxen : A historical cohort analysis. Gastroenterology 2004 ; 127 : 1322-8.

235Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis : The CLASS study : A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 ; 284 : 1247-55.

236Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients : SUCCESS-I Study. Am J Med 2006 ; 119 : 255-66.

237Hawkey CJ. COX-2 inhibitors. Lancet 1999 23 ; 353 : 307-14.

238Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med 2004 ; 117 : 100-6.

239Weideman RA, Kelly KC, Kazi S, et al. Risks of clinically significant upper gastrointestinal events with etodolac and naproxen : A historical cohort analysis . Gastroenterology 2004 ; 127 : 1322-8.

240Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestiguated dyspepsia : The canadian Adult dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE) study. Aliment Phramacol ther 2003 ; 17 :1481-91.